Glioblastoma Multiforme
Conditions
Brief summary
Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation can be included into the trial. In the phase I part the minimal tolerated dose (MTD)of BIBF 1120 in combination with radiotherapy will be investigated. Subjects in phase II will be randomised to receive reirradiation alone or reirradiation + 2 x MTD BIBF1120.
Interventions
DRUGBIBF 1120
BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
RADIATIONradiotherapy
36 Gy, 2 Gy / fraction, 18 fractions
Sponsors
Prof. Dr. Wolfgang Wick
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients with a recurrence / progression of glioblastoma either not being eligible for tumour resection or having macroscopic residual tumour after resection of the recurrence * Diagnosis of glioblastoma must be proven histologically and progress must be documented by MRI. MRI images must not be older than 2 weeks before first dosing/start of RT * Not more than two prior therapy regimens including one or two resections, one or two chemotherapies (one temozolomide containing concomitant to radiotherapy) and one radiotherapy (RT) for the brain tumour * Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at least 8 months since the end of preirradiation * Candidate for reirradiation with recurrent tumour visible on MRIT1 (Gd) and with the largest diameter measuring 1 cm to 5 cm * Informed consent * Age ≥ 18 years, smoking or non-smoking, of any ethnic origin * Karnofsky performance index (KPI) ≥ 60% * Neutrophile counts \> 1500/μl / Platelet counts \> 80.000/μl /Haemoglobin \> 10 g/dl / Serum creatinine \< 1.5-fold upper normal range / Bilirubin, AST or ALT \< 2,5-fold upper normal range unless attributed to anticonvulsants / Alkaline phosphatase \< 2,5-fold upper normal range * Adequate contraception * If on steroids, stable or decreasing treatment with steroids within 5 days before treatment start
Exclusion criteria
* More than one RT of brain, prior first radiotherapy with more than 60 Gy * Cumulative total dose on the optical chiasm \>54 Gy for 2 Gy/fraction, α/β=2 * Prior treatment with bevacizumab, iodine seeds and/or brachytherapy * Unable to undergo MRI * Past medical history of diseases with poor prognosis according to the judgement of the Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation * HIV or hepatitis infection * Pregnancy or breast feeding * Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion * Known coronary artery disease, significant cardiac arrhythmias or severe congestive heart failure (NYHA class III - IV)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximal tolerated dose of BIBF 1120 in combination with reirradiation (Phase I) | day 0, 8, 15 and 17 post-dose during phase I |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival | Time from randomization until death or disease progression |
| Objective response rates (OR) | Time from randomization until response |
| Number of participants with adverse events as a measure of safety and tolerability of BIBF1120 | Up to 90 days follow-up |
| Quality of life as determined by EORTC QLQ-C15 PAL and the EORTC brain module QLQ-BN 20 | Screening and 6-weekly after radiotherapy |
| Cognitive function determined by MMSE | Screening and 6-weekly after end of radiotherapy |
| Overall survival | Time from randomization until death |
Countries
Germany
Outcome results
None listed